Acyl-CoA dehydrogenase 9 deficiency is an ultra-rare mitochondrial disease caused by biallelic pathogenic variants in the ACAD9 gene. It is inherited in an autosomal recessive manner and primarily affects the assembly of complex I of the mitochondrial respiratory chain. Insufficient energy production particularly affects the heart and skeletal muscle, and can lead to cardiomyopathy, muscle weakness, and lactic acidosis.
Acyl-CoA dehydrogenase 9 deficiency (ACAD9 deficiency)
The ACAD9 gene encodes a mitochondrial flavoprotein with an essential function in the assembly of Complex I, a respiratory chain structure necessary for oxidative phosphorylation and ATP synthesis. ACAD9 forms an assembly intermediate with proteins such as ECSIT and NDUFAF1. It also possesses acyl-CoA dehydrogenase activity and may participate in the oxidation of long-chain fatty acids.
Pathogenic variants reduce the amount, stability, or function of ACAD9, hinder the formation of a mature Complex I, and decrease cellular energy production. The disease follows an autosomal recessive pattern, meaning an affected person typically inherits one pathogenic variant from each parent. The actual prevalence is not established and there is no confirmed epidemiological figure. Clinical expression is highly variable.
Symptoms
Onset can occur during fetal life, the neonatal period, infancy, or, less commonly, at later ages. Forms that begin during the first year are usually the most severe and are characterized by hypertrophic or dilated cardiomyopathy, heart failure, lactic acidosis, hypotonia, muscle weakness, feeding difficulties, and growth retardation. Some patients present with encephalomyopathy, developmental delay, or seizures. Juvenile or adult forms are usually milder and manifest with exercise intolerance, fatigue, myalgias, and proximal muscle weakness. Ataxia, neuropathy, and hepatic or renal involvement have also been described. The absence of cardiomyopathy does not exclude the diagnosis.
Disease management
There is currently no curative treatment. Management requires specialized follow-up, with monitoring of cardiac function, neurological development, muscle strength, and metabolic parameters such as lactate. Heart failure is treated with usual measures and, in selected patients, cardiac transplantation may be considered.
Riboflavin or vitamin B2 is the most widely used specific treatment, as it is a precursor of FAD, a cofactor necessary for the stability and function of ACAD9. In a large series, approximately two-thirds of patients evaluated showed clinical benefit, although the response is not universal and the evidence comes from retrospective and cellular studies. Its indication and dosage should be supervised by specialists. Bezafibrate and nicotinamide riboside remain experimental.
Genes analyzed
Bibliography
Repp BM, Mastantuono E, Alston CL, et al. Clinical, biochemical and genetic spectrum of 70 patients with ACAD9 deficiency: is riboflavin supplementation effective? Orphanet J Rare Dis. 2018;13:120.
Schiff M, Haberberger B, Xia C, et al. Complex I assembly function and fatty acid oxidation enzyme activity of ACAD9 both contribute to disease severity in ACAD9 deficiency. Hum Mol Genet. 2015;24(11):3238-3247.
Van Hove JLK, Friederich MW, Hock DH, et al. ACAD9 treatment with bezafibrate and nicotinamide riboside temporarily stabilizes cardiomyopathy and lactic acidosis. Mitochondrion. 2024;78:101905.
